Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Gastroenterology Clinics of North America(2014)
摘要
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including integrins and chemokine receptors, have been successfully targeted for the treatment of IBD. These agents have shown great promise for the induction and maintenance of remission for both Crohn disease and ulcerative colitis. This article discusses currently approved prototypic agents for the treatment of IBD (natalizumab, anti-α4 integrin; vedolizumab, anti-α4β7 integrin), and several other agents in the same class currently under development.
更多查看译文
关键词
Natalizumab,Vedolizumab,Etrolizumab,Integrins,Chemokine receptors,Inflammatory bowel disease,Ulcerative colitis,Crohn disease
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要